Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
75 participants
OBSERVATIONAL
2021-03-01
2023-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Diroximel Fumarate Real-world Experience in Canada and Israel
NCT04948606
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
NCT02430532
Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
NCT02472938
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
NCT04221191
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
NCT00835770
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diroximel Fumarate
Participants with RMS who are receiving diroximel fumarate orally in routine clinical practice will be enrolled.
Diroximel Fumarate
As described in the arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diroximel Fumarate
As described in the arm.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* DRF prescribed and planned to be initiated within 60 days after enrollment.
Exclusion Criteria
* Have received prior treatment with DRF.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regina Berkovich MD Phd Inc
West Hollywood, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Norton Neuroscience Institute
Louisville, Kentucky, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Glendale Neurological Associates, PC
Farmington, Michigan, United States
Memorial Healthcare
Owosso, Michigan, United States
St. Luke's Neurology
Kansas City, Missouri, United States
CentraState Healthcare System - Linda Cardinale MS Center
Freehold, New Jersey, United States
MS Center at St Barnabas
Livingston, New Jersey, United States
Multiple Sclerosis Center JSUMC
Neptune City, New Jersey, United States
Jacobs School of Medicine and Biomedical Sciences
Buffalo, New York, United States
Cone Health
Greensboro, North Carolina, United States
Providence Brain and Spine Institute
Portland, Oregon, United States
Geisinger Medical Center
Danville, Pennsylvania, United States
Hope Neurology
Knoxville, Tennessee, United States
UTHealth Neurosciences Texas Medical Center II
Houston, Texas, United States
Riverside Neurology Specialists
Newport News, Virginia, United States
Providence Medical Research Center
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US-VUM-11760
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.